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Eﬃ  cacy of idebenone on respiratory function in patients with 
Duchenne muscular dystrophy not using glucocorticoids 
(DELOS): a double-blind randomised placebo-controlled 
phase 3 trial
Gunnar M Buyse, Thomas Voit, Ulrike Schara, Chiara S M Straathof, M Grazia D’Angelo, Günther Bernert, Jean-Marie Cuisset, Richard S Finkel, 
Nathalie Goemans, Craig M McDonald, Christian Rummey, Thomas Meier, for the DELOS Study Group
Summary
Background Cardiorespiratory failure is the leading cause of death in Duchenne muscular dystrophy. Based on 
preclinical and phase 2 evidence, we assessed the eﬃ  cacy and safety of idebenone in young patients with Duchenne 
muscular dystrophy who were not taking concomitant glucocorticoids.
Methods In a multicentre phase 3 trial in Belgium, Germany, the Netherlands, Switzerland, France, Sweden, Austria, 
Italy, Spain, and the USA, patients (age 10–18 years old) with Duchenne muscular dystrophy were randomly assigned 
in a one-to-one ratio with a central interactive web response system with a permuted block design with four patients 
per block to receive idebenone (300 mg three times a day) or matching placebo orally for 52 weeks. Study personnel 
and patients were masked to treatment assignment. The primary endpoint was change in peak expiratory ﬂ ow (PEF) 
as percentage predicted (PEF%p) from baseline to week 52, measured with spirometry. Analysis was by intention to 
treat (ITT) and a modiﬁ ed ITT (mITT), which was prospectively deﬁ ned to exclude patients with at least 20% diﬀ erence 
in the yearly change in PEF%p, measured with hospital-based and weekly home-based spirometry. This study is 
registered with ClinicalTrials.gov, number NCT01027884.
Findings 31 patients in the idebenone group and 33 in the placebo group comprised the ITT population, and 
30 and 27 comprised the mITT population. Idebenone signiﬁ cantly attenuated the fall in PEF%p from baseline to 
week 52 in the mITT (–3·05%p [95% CI –7·08 to 0·97], p=0·134, vs placebo –9·01%p [–13·18 to –4·84], p=0·0001; 
diﬀ erence 5·96%p [0·16 to 11·76], p=0·044) and ITT populations (–2·57%p [–6·68 to 1·54], p=0·215, vs –8·84%p 
[–12·73 to –4·95], p<0·0001; diﬀ erence 6·27%p [0·61 to 11·93], p=0·031). Idebenone also had a signiﬁ cant eﬀ ect on 
PEF (L/min), weekly home-based PEF, FVC, and FEV1. The eﬀ ect of idebenone on respiratory function outcomes was 
similar between patients with previous corticosteroid use and steroid-naive patients. Treatment with idebenone was 
safe and well tolerated with adverse event rates were similar in both groups. Nasopharyngitis and headache were the 
most common adverse events (idebenone, eight [25%] and six [19%] of 32 patients; placebo, nine [26%] and seven 
[21%] of 34 patients). Transient and mild diarrhoea was more common in the idebenone group than in the placebo 
group (eight [25%] vs four [12%] patients).
Interpretation Idebenone reduced the loss of respiratory function and represents a new treatment option for patients 
with Duchenne muscular dystrophy.
Funding Santhera Pharmaceuticals.
Introduction
Duchenne muscular dystrophy is the most common 
and devastating type of muscular dystrophy.1 
Progressive weakness of respiratory muscles leads to 
restrictive pulmonary disease that evolves into 
respiratory compli cations and early morbidity and 
mortality.2–7 Glucocorticoids are the only medications 
that can slow the decline in muscle strength and 
function and delay the onset and progression of 
respiratory dysfunction.8–10 However, not all patients 
with Duchenne muscular dystrophy respond to steroids 
to the same extent and the well known side-eﬀ ects of 
steroids restrict their clinical use, particularly in 
non-ambulatory patients in the later stage of the 
disease. In a natural history study, 42% of patients with 
Duchenne muscular dystrophy aged 10 years and older 
had never used glucocorticoids or discontinued their 
use because of side-eﬀ ects and tolerability limitations.9 
Consequently, for many patients with Duchenne 
muscular dystrophy there are no pharma cological 
treatment options at about the age when patients 
become non-ambulatory and the decline in their 
respiratory function becomes clinically relevant.
The short-chain benzoquinone idebenone is a potent 
antioxidant and inhibitor of lipid peroxidation that 
is capable of stimulating mitochondrial electron ﬂ ux 
and cellular energy production.11,12 The results of a 
placebo-controlled study in the mdx mouse showed 
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signiﬁ cant cardioprotective and voluntary exercise 
performance eﬀ ects after idebenone treatment.13 The 
ﬁ ndings from a phase 2 randomised placebo-controlled 
trial (DELPHI) showed beneﬁ cial eﬀ ects of idebenone on 
early functional cardiac and respiratory markers.14 
An important ﬁ nding from the DELPHI study was that 
patients treated with idebenone had stabilised peak 
expiratory ﬂ ow as percentage predicted (PEF%p), 
a marker of expiratory muscle strength compared with 
a reduction in patients given placebo. Additional analyses 
indicated that the eﬀ ect of idebenone on respiratory 
function outcomes was larger in patients not taking 
concomitant glucocorticoids.15
We investigated the eﬃ  cacy, tolerability, and safety of 
idebenone in a conﬁ rmatory phase 3 trial in patients with 
Duchenne muscular dystrophy not taking concomitant 
glucocorticoids.
Methods
Study design and patients
Patients aged 10–18 years with a documented diagnosis 
of Duchenne muscular dystrophy were eligible for 
inclusion in this phase 3 trial. Recruiting centres were 
in Belgium, Germany, the Netherlands, Switzerland, 
France, Sweden, Austria, Italy, Spain, and the USA. 
A full list of inclusion, exclusion, and withdrawal criteria 
is provided in the appendix.
Patients were enrolled between July 27, 2009 (study 
start date), and Dec 14, 2012; the study end date (last 
patient completed the study) was Jan 14, 2014.
Randomisation and masking
We used an interactive web response system to randomly 
allocate patients in a one-to-one ratio with a permuted 
block design with four patients per block to ﬁ lm-coated 
tablets of idebenone (150 mg per tablet, Raxone/Catena, 
Santhera Pharmaceuticals, Liestal, Switzerland; 300 mg 
three times a day, orally, during meals) or matching 
placebo for 52 weeks. Two siblings of patients who were 
already randomly allocated were assigned to the same 
group as their siblings to avoid mix up of study medication. 
Randomisation was balanced for PEF%p at baseline 
(two PEF%p strata: <40%p and 40–80%p). All study 
personnel and patients were masked to treatment group 
assignment. Compliance was monitored with entries in a 
patient’s diary and pill counts. After enrolment, safety and 
eﬃ  cacy were assessed during hospital visits at weeks 13, 
26, 39, and 52. Additional safety assessments were 
undertaken 4 weeks after randomisation and at the 
follow-up visit 4 weeks after the week 52 visit or after early 
discontinuation of study medication. Patients were 
instructed and educated to assess their weekly respiratory 
function (peak expiratory ﬂ ow [PEF] and forced expiratory 
volume in 1 s [FEV1]) using the hand-held ASMA-1 device 
(usb model 4000, Vitalograph, Maids Moreton, UK) at 
home. The study had several protocol amendments, 
which are listed in the appendix.
The trial and any changes to the protocol were approved 
by relevant national authorities and the institutional 
review boards or independent ethics committees in the 
countries of the participating centres and done in 
accordance with good clinical practice and the principles 
of the Declaration of Helsinki. We obtained written 
informed consent from patients.
Outcomes
The primary objective was to assess the eﬃ  cacy of 
idebenone, compared with placebo, in improving or 
reducing loss of respiratory function, measured by a 
qualiﬁ ed, trained, and certiﬁ ed evaluator at each centre 
in accordance with standardised procedures and inter-
national guidelines. Pulmonary function tests were done 
at each hospital visit with a Pneumotrac Spirometer 
6800 (Vitalograph) and maximal static airway pressures 
were assessed with a MicroRPM instrument (Medical 
Supply Store, Chorley, UK). At each hospital visit, PEF 
and FEV1 were also measured with the patient’s portable See Online for appendix
Figure 1: Trial proﬁ le
PEF%p=peak expiratory ﬂ ow as percentage predicted. ITT=intention to treat. mITT=modiﬁ ed intention to treat. 
*Two patients were unable to form a mouth seal, two had PEF %p greater than 80% at baseline, two required assisted 
ventilation, one patient was using steroids, one required spinal ﬁ xation surgery, two patients were unable to comply 
with study procedures, one patient withdrew informed consent, one was a smoker, and four patients had one or more 
other reasons for exclusion.
96 patients screened
65 randomly assigned
 2 non-randomly assigned
29 excluded
 13 PEF%p not within 15%
 16 other reasons*
66 treated
1 not treated 
 (withdrew consent)
30 mITT population
1 >20% diﬀerence in yearly 
 change in PEP%p
27 mITT population
6 >20% diﬀerence in yearly 
 change in PEP%p
4 early discontinuation
 2 adverse events
 1 non-compliance
 1 protocol violation
7 early discontinuation
 1 adverse event
 1 non-compliance
 1 withdrawal of consent
 1 lost to follow-up
 3 spinal ﬁxation surgery
34 placebo (safety population)
30 completed study 25 completed study
32 idebenone (safety population)
33 ITT population 31 ITT population
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ASMA-1 device. The primary endpoint was the change in 
spirometer-measured PEF%p from baseline to week 52. 
Secondary respiratory eﬃ  cacy endpoints were changes 
in PEF, forced vital capacity (FVC), FEV1, maximum 
inspiratory pressure (MIP), maximum expiratory 
pressure (MEP), and peak cough ﬂ ow—assessed during 
hospital visits at weeks 13, 26, 39, and 52. PEF and FEV1 
were also measured weekly at home with the portable 
ASMA-1 device. The highest value from a minimum of 
three and up to ﬁ ve consecutive manoeuvres was used 
for each assessment. Percentage predicted (%p) values 
were calculated with established equations (appendix).16–21 
Safety assessments were physical exam ination, vital 
signs, and blood or urine sampling. Cardiac function 
(transthoracic echocardiography and 12-lead electro-
cardiography [ECG]) was assessed for safety monitoring, 
but not as eﬃ  cacy endpoints. Blood and urine analyses 
were done at BARC Europe NV (Gent, Belgium). Adverse 
events were graded for severity and relation to the study 
drug and coded with the MedDRA dictionary 
(version 14.0).
Statistical analysis
A statistical analysis plan was prepared before the database 
was locked. The primary analysis of the primary endpoint 
(change in PEF%p from baseline to week 52) was to be 
made in a modiﬁ ed intention-to-treat population (mITT; 
appendix), which excluded patients with at least 20% 
diﬀ erence in the yearly change in PEF%p measured with 
hospital-based spirometry and home-based ASMA-1 
assessments. Like all the other endpoints, the primary 
endpoint was also calculated in the full ITT population. 
Continuous variables were analysed with a mixed model 
for repeated measurements with treatment group, visit, 
and interaction between treatment group and visit used as 
ﬁ xed factors in the model and baseline assessment used as 
a covariate. For responder analyses, responders were 
deﬁ ned as patients who did not have deterioration in 
respiratory function tests. Responder rates were compared 
between treatment groups with the Cochran-Mantel-
Haenszel test with missing data imputed with the last 
observation carried forward method. All hypotheses tested 
and 95% CIs presented were two-sided and p values of less 
than 5% were signiﬁ cant without adjustment for 
multiplicity and regarded as exploratory except for the 
primary endpoint. The sample size for the study provided 
80% power to detect a diﬀ erence of 10∙3% in PEF%p. 
A planned futility analysis was done after all 64 patients had 
been randomly assigned and 37 had completed the trial. 
This analysis, done by the data and safety monitoring 
board, conﬁ rmed non-futility of the trial.
This study is registered with ClinicalTrials.gov, number 
NCT01027884.
Role of the funding source
The study funder was involved in the study design, and 
data gathering and analysis. The investigators and all 
authors had sole discretion in the data analysis and 
interpretation, writing of the report, and the decision to 
submit for publication.
Results
96 patients were screened and 29 were excluded from 
participation because they did not meet inclusion or 
exclusion criteria. 65 patients were randomly assigned 
and two patients were allocated to the same treatment as 
their randomly assigned siblings (ﬁ gure 1). One patient 
never took study medication, resulting in 66 patients 
who were treated and included in the safety population 
(34 in the placebo group and 32 in the idebenone group). 
55 patients completed the trial and 11 withdrew or 
Idebenone group 
(n=31)
Placebo group 
(n=33)
Age (years) 13·5 (2·7) 15·0 (2·5)
Weight (kg) 55·3 (18·3) 61·9 (18·0)
Height* (cm) 157·4 (11·3) 162·4 (12·4)
Body-mass index (kg/m²) 22·0 (5·9) 23·4 (5·6)
Ethnic origin
White 29 (94%) 31 (94%)
Oriental 1 (3%) 0
Hispanic 0 1 (3%)
Other 1 (3%) 1 (3%)
Previous glucocorticoid use
Yes 17 (55%) 19 (58%)
No 14 (45%) 14 (42%)
Time since last glucocorticoid use 
(years)
2·9 (1·8) 4·3 (2·2)
Patient in wheelchair 28 (90%) 31 (94%)
Baseline PEF%p
<40%p 5 (16%) 7 (21%)
40–80%p 26 (84%) 26 (79%)
Baseline respiratory function test
PEF%p 53·5 (10·3) 54·2 (13·2)
PEF (L/min) 217·7 (48·6) 233·8 (59·6)
FVC%p 55·3 (15·8) 50·4 (20·0)
FVC (L) 1·9 (0·5) 1·9 (0·5)
FEV1%p 53·3 (15·1) 49·7 (18·3)
FEV1 (L) 1·54 (0·33) 1·71 (0·57)
MIP%p 43·5 (22·2) 38·5 (16·9)
MIP (cm H₂O) 47·3 (24·4) 44·6 (16·9)
MEP%p 28·3 (12·2) 25·1 (12·2)
MEP (cm H₂O) 40·6 (15·6) 39·7 (16·6)
PCF (L/min) 243·0 (70·7) 256·4 (50·5)
Data are mean (SD) or number (%). ITT=intention-to-treat population. PEF%p=peak 
expiratory ﬂ ow as percentage predicted. FVC%p=forced vital capacity as percentage 
predicted. FVC=forced vital capacity. FEV1%p=forced expiratory volume in 1 s as 
percentage predicted. FEV1=forced expiratory volume in 1 s. MIP%p=maximum 
inspiratory pressure as percentage predicted. MIP=maximum inspiratory pressure. 
MEP%p=maximum expiratory pressure as percentage predicted. MEP=maximum 
expiratory pressure. PCF=peak cough ﬂ ow. *Derived from ulnar length.20,21
Table 1: Demographic characteristics and baseline pulmonary function 
values in the ITT population
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discontinued the drug during the study. The ITT 
population (33 patients in the placebo group and 31 in 
the idebenone group) excluded patients who were 
allocated to the same treatment as their siblings and the 
mITT population prospectively excluded seven patients 
(27 and 30 patients; appendix).
Patients’ characteristics at baseline were balanced 
between the treatment groups (table 1), except for younger 
Figure 2: Results of respiratory function test outcomes in the ITT population
(A) PEF%p. (B) PEF. (C) FVC%p. (D) FVC. (E) FEV1%p. (F) FEV1. Data are mean (SE), unless otherwise indicated; treatment diﬀ erences and p values are shown for the 
between-group comparisons. ITT=intention-to-treat population. PEF%p=peak expiratory ﬂ ow as percentage predicted. PEF=peak expiratory ﬂ ow. FVC%p=forced vital 
capacity as percentage predicted. FVC=forced vital capacity. FEV1%p=forced expiratory volume in 1 s as percentage predicted. FEV1=forced expiratory volume in 1 s.
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age in the idebenone group. Time since last steroid use 
before enrolment in the trial was well above the required 
12-month washout in both groups (table 1). At baseline 
more than 90% of patients were non-ambulatory and 
most patients presented with PEF%p of 40–80%p (table 1).
Compliance with study medication was good with 
similar exposures between treatment groups (mean 
332·7 days [SD 71·9] in the idebenone group and 
344·8 days [65·1] in the placebo group).
Patients were well balanced between treatment groups 
for baseline respiratory function variables (table 1). The 
primary eﬃ  cacy variable (PEF%p), as measured with 
hospital-based spirometry or with the home-based 
ASMA-1 device, was similar between groups at baseline 
(appendix), conﬁ rming the reliability of the data obtained.
For the primary endpoint (mITT population), there 
was a signiﬁ cant fall in PEF%p by 9·01%p (95% CI 
–13·18 to –4·84; p=0·0001) from baseline to week 52 in 
the placebo group compared with a non-signiﬁ cant 
decline of 3·05%p (–7·08 to 0·97; p=0·134) in the 
idebenone group, resulting in a signiﬁ cant diﬀ erence 
between treatment groups of 5·96%p (0·16 to 11·76; 
p=0·044) at week 52 and this represented a 66% 
reduction in loss of PEF%p. The eﬀ ect of idebenone was 
signiﬁ cant at week 26 (p=0·007) and week 39 (p=0·034) 
and at all post-baseline assessment timepoints together 
(p=0·018). Baseline PEF%p values in the mITT 
population were well balanced (idebenone 53·1%p [SD 
10·2] and placebo 54·3%p [13·5]). Similar results were 
obtained for the full ITT population with a signiﬁ cant 
decline in PEF%p from baseline to week 52 in the 
placebo group by 8·84%p (95% CI –12·73 to –4·95; 
p<0·0001) compared with a non-signiﬁ cant decline of 
2·57%p (–6·68 to 1·54; p=0·215) in the idebenone 
group, resulting in signiﬁ cant diﬀ erences between 
treatment groups at week 52 (6·27%p [0·61 to 11·93]; 
p=0·031) and at other study timepoints (ﬁ gure 2A; 
table 2). Results for the primary endpoint, assessed with 
standard spirometry during hospital visits, were 
conﬁ rmed with the results for the secondary PEF 
Idebenone group (n=31) Placebo group (n=33) Group diﬀ erence
Mean (SD) Change (95% CI) p value Mean (SD) Change (95% CI) p value Diﬀ erence (95% CI) p value
PEF%p
Baseline 53·5 (10·3) 54·2 (13·2)
Change from baseline (MMRM)
Week 52 –2·57 (–6·68 to 1·54) 0·215 –8·84 (–12·73 to –4·95) <0·0001 6·27 (0·61 to 11·93) 0·031
Weeks 13–52 –1·32 (–4·59 to 1·94) 0·421 –7·84 (–11·00 to –4·69) <0·0001 6·52 (1·98 to 11·06) 0·006
PEF (L/min)
Baseline mean (SD) 217·7 (48·6) 233·8 (59·6)
Change from baseline (MMRM)
Week 52 1·72 (–16·71 to 20·14) 0·853 –26·38 (–43·81 to –8·95) 0·004 28·09 (2·69 to 53·50) 0·031
Weeks 13–52 1·48 (–12·96 to 15·93) 0·838 –25·65 (–39·62 to –11·67) 0·001 27·13 (6·97 to 47·29) 0·009
ITT=intention to treat. MMRM=mixed model for repeated measurements. PEF=peak expiratory ﬂ ow. PEF%p=peak expiratory ﬂ ow as percentage predicted.
Table 2: Change in PEF from baseline to week 52 and across all post-baseline assessment timepoints (weeks 13–52) in the ITT population
Figure 3: Comparative eﬀ ect sizes in favour of idebenone in PEF%p at week 52 with diﬀ erent assessment methods, populations, and methods of imputation 
for missing data
PEF%p=peak expiratory ﬂ ow as percentage predicted. mITT=modiﬁ ed intention to treat. PP=per protocol. LOCF=last observation carried forward. ITT=intention to 
treat. *Two patients (one in the placebo group and one in the idebenone group) were identiﬁ ed as aﬀ ecting the result of the primary analysis; these patients were 
excluded in this post-hoc analysis.
Eﬀect size (95% CI)
Assessment methods (ITT population)
Hospital based 
Home based, linear regression 
Home based, window approach 
Populations and imputation methods
mITT
PP 
Completers 
LOCF, ITT 
Cook’s D*, ITT 
6·27 (0·61 to 11·93)
6·84 (–0·15 to 13·83)
7·24 (0·82 to 13·66)
5·96 (0·16 to 11·76)
6·28 (–0·48 to 13·04)
5·84 (–0·38 to 12·07)
6·39 (0·99 to 11·79)
6·29 (1·03 to 11·54)
p value
0·031
0·055
0·028
0·044
0·068
0·065
0·021
0·020
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50 10
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endpoints, measured at home with the ASMA-1 device, 
through linear regression analysis for the yearly change 
(p=0·055) and mean of data obtained during 6 weeks 
around hospital visits (p=0·028; ﬁ gure 3; appendix). 
Sensitivity analyses were done to assess the robustness 
of the results by applying diﬀ erent imputation methods 
for missing data in the ITT population, analysing a 
diﬀ erent population, and by excluding patients likely to 
aﬀ ect the results (ﬁ gure 3). The results show that the 
treatment eﬀ ect was not altered by diﬀ erent assumptions 
about missing data or by the exclusion of data for 
patients deﬁ ned as being in diﬀ erent populations.
Diverging trajectories between treatment groups were 
also noted in PEF with signiﬁ cant diﬀ erences between 
treatment groups at week 52 (28·1 L/min [95% CI 2·69 
to 53·50]; p=0·031) and at other visit timepoints (ﬁ gure 
2B; table 2; appendix). Other respiratory function 
endpoints such as FVC%p, FVC, FEV1%p, and FEV1 
showed a consistent pattern with treatment diﬀ erences, 
lending support to the eﬃ  cacy of idebenone over placebo 
in the preservation of respiratory function (ﬁ gure 2C–F; 
appendix). Change from baseline to week 52 was well 
correlated between PEF%p and FVC%p (r²=0·333; 
p<0·0001; appendix). No signiﬁ cant diﬀ erences were 
noted in the change from baseline to week 52 for MIP, 
MEP, and peak cough ﬂ ow (data not shown). Also, no 
treatment eﬀ ect was noted in upper limb strength 
(measured with hand-held myometry) and function 
(assessed with the Brooke’s scale) and patient-reported 
outcomes assessed with Pediatric Quality of Life 
Inventory (data not shown).
Since the study population was a mix of patients who 
in the past had used glucocorticoids and patients who 
had never used steroids (table 1), it was of interest to 
assess whether previous steroid use aﬀ ected the 
outcome of respiratory function tests. Post-hoc analysis 
showed that respiratory function test outcomes were 
similar between patients with previous steroid use and 
steroid-naive patients (appendix). To investigate the 
eﬀ ect of age, dichotomised age at baseline (≤14 years or 
>14 years) and the interaction between age and treatment 
group were included as ﬁ xed factors in the model in a 
post-hoc analysis. Both these factors were non-
signiﬁ cant for PEF%p (p=0·384 and p=0·819) and 
FVC%p (p=0·141 and p=0·941), showing that age did 
not aﬀ ect the outcome for PEF%p and FVC%p. 
Treatment eﬀ ects were also assessed for the ITT patient 
subgroups separated by the median age (14 years). A 
positive treatment eﬀ ect in favour of idebenone was 
evident from this post-hoc analysis for patients younger 
and older than 14 years of age (appendix).
Positive outcomes favouring idebenone over placebo 
were further supported by the results of prespeciﬁ ed 
responder analyses, which showed a higher proportion 
of idebenone-treated patients who did not deteriorate in 
respiratory function tests between baseline and week 52 
(table 3).
Idebenone’s eﬀ ects were also supported with clinical 
ﬁ ndings. In a prespeciﬁ ed analysis, we counted the 
number of patients who at any time during the trial 
dropped below 160 L/min in peak cough ﬂ ow, a clinically 
meaningful threshold below which cough is no longer 
eﬀ ective enough to provide adequate mucociliary 
clearance and consensus care recommends mechanical 
cough assistance.7,22,23 In the ITT population there were 
six (18%) of 33 patients in the placebo group but only 
one (4%) of 25 patients in the idebenone group above the 
threshold at baseline falling below the 160 L/min 
threshold. Moreover, the results of a post-hoc analysis 
showed that there were ﬁ ve (16%) of 32 patients in the 
placebo group but only one (3%) of 31 patients in the 
idebenone group who fell below 1 L in FVC, a clinically 
important threshold and predictor of early mortality.24 
Also, the number of patients reporting upper respiratory 
tract infection-related adverse events was lower in the 
idebenone group than in the placebo group (appendix). 
Similarly, there were more patients in the placebo group 
reporting lower respiratory tract infection-related 
adverse events (bronchitis and pneumonia) than in the 
idebenone group, although the diﬀ erence was not 
signiﬁ cant (appendix).
Treatment with idebenone was safe and well tolerated. 
No deaths occurred during the study. Of the 66 patients 
included in the safety analyses, 62 (94%) had at least 
one adverse event: 30 (94%) in the idebenone group and 
32 (94%) in the placebo group. Nasopharyngitis (26%) 
and headache (20%) were the most common adverse 
Idebenone 
group 
(n=31)
Placebo 
group 
(n=33)
p value*
Patients who did not deteriorate from baseline to week 52
PEF%p 14 (45%) 8 (24%) 0·081
PEF 18 (58%) 9 (27%) 0·013
FVC%p 7 (23%) 3 (9%) 0·141
FVC 15 (48%) 6 (18%) 0·011
FEV1%p 14 (45%) 4 (12%) 0·004
FEV1 18 (58%) 11 (33%) 0·049
Patients who did not deteriorate by 10% or more from baseline 
to week 52
PEF%p 22 (71%) 11 (33%) 0·003
PEF 26 (84%) 16 (48%) 0·003
FVC%p 13 (42%) 8 (24%) 0·135
FVC 24 (77%) 17 (52%) 0·032
FEV1%p 18 (58%) 13 (39%) 0·138
FEV1 22 (71%) 17 (52%) 0·114
Data are number (%), unless otherwise indicated. ITT=intention-to-treat 
population. PEF%p=peak expiratory ﬂ ow as percentage predicted. FVC%p=forced 
vital capacity as percentage predicted. FVC=forced vital capacity. FEV1%p=forced 
expiratory volume in 1 s as percentage predicted. FEV1=forced expiratory volume 
in 1 s. *Cochran-Mantel-Haenszel test.
Table 3: Responder rates in the ITT population for respiratory function 
test results
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events without diﬀ erences in their incidence between the 
treatment groups (appendix). Transient and mild 
diarrhoea, a known side-eﬀ ect of idebenone intake, was 
more common in idebenone-treated patients (25% vs 
12%), whereas constipation was more common in the 
placebo group than in the idebenone group (18% vs 9%; 
appendix). Most adverse events were of mild or moderate 
intensity. Serious adverse events were reported in 6% 
and severe adverse events in 3% of idebenone-treated 
patients and in 15% and 12% of placebo-treated patients, 
none of which were classiﬁ ed as related to intake of study 
medication (appendix). The adverse events that led to 
discontinuation of treatment were sleep apnoea 
syndrome (n=1) and diarrhoea (n=1) in the idebenone 
group and supraventricular arrhythmia and respiratory 
failure with pneumonia in the placebo group (all in same 
patient). None of the adverse events that led to premature 
discontinuation from the study were judged by the 
investigator to be related to study treatment. There was 
no evidence for a clinically relevant eﬀ ect of idebenone 
on any haematological or clinical chemistry variable, vital 
signs, physical examinations, or results from ECG and 
echocardiography assessments.
Discussion
The DELOS trial met its primary objective and the results 
showed that idebenone signiﬁ cantly reduced the loss of 
respiratory function in patients with Duchenne muscular 
dystrophy.
Ventilatory support and the chronic use of gluco-
corticoids have contributed to increased longevity in 
patients with Duchenne muscular dystrophy. Never-
theless, respiratory complications continue to be a 
main cause of early morbidity and mortality in steroid-
treated patients and a subset of patients with Duchenne 
muscular dystrophy do not respond to or do not tolerate 
steroid treatment. In an attempt to develop novel 
treatment options, and continuing from previous 
studies,13,14 we have now investigated the eﬃ  cacy and 
safety of idebenone in patients with Duchenne 
muscular dystrophy in the ﬁ rst ever successful phase 3 
study of patients with this disease (panel).
Based on the results from a phase 2 study,14 PEF was 
selected as the primary eﬃ  cacy variable, which in the 
absence of bronchial obstruction is a measure of 
expiratory muscle strength. In patients with Duchenne 
muscular dystrophy, progressive weakness of chest wall 
muscles precedes weakness of the diaphragm (used 
mainly for inspiratory function) and leads to restrictive 
lung volume changes (ie, reduced FVC).4,25–28 Compared 
with other respiratory variables, FVC is less sensitive to 
mild muscle weakness in the early stages of the 
disease.9,29 Loss of lung volume initially results from the 
inability to pull up the respiratory system to total lung 
capacity and to push it down to residual volume. In the 
later stage of disease, additional restriction occurs as a 
result of progressive muscle ﬁ brosis and changes in 
lung and chest wall recoil. Therefore, respiratory 
strength might be more sensitive to treatment inter-
vention than is lung volume, because this is aﬀ ected not 
only by respiratory muscle strength but also by thoracic 
wall compliance and deformities. Additionally, abnormal 
respiratory mech anics in Duchenne muscular dystrophy 
are not restricted to the lungs and chest wall and might 
also involve the upper airways.30 Here, weakness of 
pharyngeal dilator muscles decreases upper airway 
calibre, causing an increase in upper airway resistance 
during inspiration, which imposes an increased 
mechanical load on the diaphragm and other inspiratory 
muscles.31 Therefore, PEF is a measure not only of 
expiratory strength but also inspiratory eﬀ ort and upper 
airway resistance.32,33
In the DELOS trial, there was a signiﬁ cant fall in 
PEF%p from baseline to week 52 in the placebo group 
compared with a non-signiﬁ cant decline in the idebenone 
group, resulting in a signiﬁ cant and clinically relevant 
idebenone treatment eﬀ ect. No treatment eﬀ ect was 
noted for MIP and MEP, which at baseline were more 
severely aﬀ ected than were the expiratory ﬂ ow and lung 
volume variables. These low baseline values are in line 
with previous data indicating that maximum static airway 
Panel: Research in context
Systematic review
We searched PubMed and clinical trial registries for registrations and reports of 
randomised double-blind placebo-controlled trials of idebenone in the treatment of 
patients with Duchenne muscular dystrophy. We identiﬁ ed only one study (phase 2 
DELPHI trial; ClinicalTrials.gov, number NCT00654784). The phase 3 DELOS trial of 
idebenone in patients with dystrophin-deﬁ cient muscular dystrophy was based on 
existing evidence: an observer-masked long-term placebo-controlled study in the mdx 
mouse model of Duchenne muscular dystrophy and the proof-of-concept phase 2 DELPHI 
trial in patients with Duchenne muscular dystrophy. The results of the animal model study 
showed phenotypic correction with substantial cardioprotection and voluntary exercise 
performance improvement. DELPHI’s results showed a signiﬁ cant respiratory eﬀ ect of 
idebenone on peak expiratory ﬂ ow (primary endpoint in DELOS). The design of the DELOS 
trial was based on the DELPHI ﬁ ndings and scientiﬁ c advice consultation with regulatory 
authorities. The DELPHI and DELOS trials had some diﬀ erences in drug dosing and 
patients’ characteristics. In DELPHI, idebenone was dosed at 450 mg daily (because of few 
safety data available at the time); in DELOS we used 900 mg daily. Patients in DELPHI 
were aged 8–16 years and were a mix of individuals not using concomitant 
glucocorticoids and those on steroids for Duchenne muscular dystrophy. The DELOS study 
population consisted of 10–18-year-old patients not taking concomitant glucocorticoids.
Interpretation
To the best of our knowledge, we report for the ﬁ rst time a phase 3 randomised 
controlled trial in patients with Duchenne muscular dystrophy with a positive 
outcome. Signiﬁ cant and clinically relevant results for primary and secondary 
endpoints showed that idebenone reduced the loss of respiratory function in 
10–18-year-old patients with Duchenne muscular dystrophy who were not using 
concomitant glucocorticoids. Also, idebenone was safe and well tolerated. The 
relevance of modifying the natural course of respiratory disease in Duchenne muscular 
dystrophy is emphasised in clinical practice where respiratory failure leads to 
ventilator-dependency and continues to be the predominant cause of early death in 
patients with Duchenne muscular dystrophy. 
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pressures are regarded as early markers of respiratory 
dysfunction in Duchenne muscular dystrophy and their 
much reduced values at study start could have precluded 
the detection of any treatment eﬀ ect.
Morbidity and mortality in patients with Duchenne 
muscular dystrophy are associated with progressive 
restrictive lung disease and irreversible loss of lung 
function, commonly measured as a reduction in FVC.24 
Therefore, reducing the decline in FVC, as shown in this 
trial, is of clinical relevance. In DELOS, the decrease in 
FVC in the placebo group is similar to recent natural 
history data in steroid-naive patients with Duchenne 
muscular dystrophy.24,34 Furthermore, the idebenone 
eﬀ ect size in DELOS is similar to outcomes reported for 
investigational treatments of idiopathic pulmonary 
ﬁ brosis, another restrictive lung disease (appendix).35,36
Results from a phase 2 trial (DELPHI) showed a larger 
eﬀ ect size of idebenone on respiratory function in 
patients not taking concomitant glucocorticoids than in 
patients who took steroids.15 To account for this 
inﬂ uence, only patients not using concomitant steroids 
were enrolled in DELOS. Subgroup analyses showed 
that the eﬀ ect sizes in favour of idebenone for PEF, FVC, 
and FEV1 were generally similar between patients who 
were steroid naive and those who had used steroids in 
the past for Duchenne muscular dystrophy. These 
results are in agreement with previous ﬁ ndings that 
lung volume measurements in past users of steroids are 
not diﬀ erent from steroid-naive patients,9 indicating that 
the thera peutic eﬀ ect of steroids on respiratory function 
is diminished after their discontinuation. Although data 
from the current trial were obtained in patients not 
using steroids, there is no reason a priori why idebenone 
could not also be exerting a treatment eﬀ ect in patients 
using steroids concomitantly. However, it might be 
challenging to convincingly show this additive eﬀ ect of 
idebenone on top of steroids.15
The results of DELOS showed a somewhat larger eﬀ ect 
size for PEF%p and FVC%p in the subgroup of patients 
aged 14 years and younger than in the older patients 
(appendix), indicating that patients may derive a larger 
beneﬁ t from idebenone if treatment is initiated early.
Idebenone was safe and well tolerated with frequency 
and severity of adverse events that were similar between 
treatment groups, in line with previous reports.14,37
Limitations of this study are related to the sample size 
and treatment duration. The study had several protocol 
amendments (appendix), most notably an amendment 
that deﬁ ned the ﬁ nal study population to the subgroup 
of patients not using glucocorticoids. No patients using 
concomitant glucocorticoids were enrolled in the study. 
The robustness of the outcome was assessed with 
sensitivity analyses by use of diﬀ erent imputation 
methods, by excluding patients whose inclusion might 
aﬀ ect the outcome, and with diﬀ erent assessment 
methods and intervals. Overall, the data set is robust, 
thereby alleviating concerns that might result from the 
small sample size of the study. The duration of a 
placebo-controlled trial in children with Duchenne 
muscular dystrophy with advanced disease inevitably 
has to be limited by ethical reasons. Although a study of 
12 months cannot provide data on hard outcome 
measures such as time to assisted ventilation or death, 
this limitation is mitigated by the consistency of the 
idebenone eﬀ ects on respiratory function outcomes 
(PEF, FVC, and FEV1) together with clinically relevant 
ﬁ ndings. Speciﬁ cally, the proportion of patients with 
reductions in FVC or peak cough ﬂ ow below crucial 
thresholds,22–24,38 known to be predictive of imminent 
ventilatory failure, and the reduced number of upper 
airway tract infections in the idebenone group, are 
strongly supportive for the clinical meaningfulness of 
the idebenone eﬀ ect. The overall number of lower airway 
tract infections reported during the 1-year follow-up was 
small and, therefore, no conclusion can be drawn. 
However, the numerical diﬀ erence in favour of 
idebenone treatment is encouraging and merits further 
investigation during longer follow-up.
In the past, improved patient care with best-practice 
recommendations and the introduction of glucocorticoids 
has greatly increased the survival time of patients with 
Duchenne muscular dystrophy.7,8,39,40 Nevertheless, loss of 
respiratory function continues to be a predominant cause 
of early morbidity and mortality in patients with 
Duchenne muscular dystrophy. Eﬃ  cacy data from this 
trial show that idebenone signiﬁ cantly reduced the loss 
of respiratory function in patients with Duchenne 
muscular dystrophy who were not taking concomitant 
glucocorticoids. With its favourable safety and tolerability 
proﬁ les, idebenone therefore is a suitable treatment 
option to ameliorate a life-threatening complication of 
Duchenne muscular dystrophy.
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